Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $52.98 and last traded at $52.86, with a volume of 81314600 shares. The stock had previously closed at $50.00.
Key Stories Impacting Terns Pharmaceuticals
Here are the key news stories impacting Terns Pharmaceuticals this week:
- Positive Sentiment: Merck agreed to acquire Terns for about $6.7 billion in cash, bringing a late‑stage leukemia candidate into MRK’s oncology lineup—this deal narrative is the primary bullish catalyst supporting a sharp rally toward the $53 offer price. Merck to Buy Terns for $6.7 Billion to Grow in Blood Cancers
- Positive Sentiment: Analysts and news outlets emphasize Merck’s acquisition as strategic—adding a leukemia asset as Keytruda faces patent pressure—supporting upside sentiment for TERN shares. Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
- Positive Sentiment: Market commentary notes a possible bidding‑war dynamic after the Merck approach, which can lift the stock above the announced offer if other suitors emerge. Merck’s deal for Terns sparks debate over a possible biotech bidding war
- Positive Sentiment: Market reaction has pushed TERN to a new 52‑week high as investors price in the deal and potential takeover premium. Terns Pharmaceuticals (NASDAQ:TERN) Hits New 52-Week High – Still a Buy?
- Neutral Sentiment: HC Wainwright reiterated a “Neutral” rating and published FY2030 estimates and a $53.00 price target—its view aligns with the announced cash price, leaving limited analyst upside ahead of deal closure. HC Wainwright Reaffirms Neutral Rating for Terns Pharmaceuticals (NASDAQ:TERN)
- Negative Sentiment: Unusually large put option activity was reported (7,719 puts, a ~96% increase vs. typical put volume), suggesting some traders are hedging or positioning for downside/uncertainty around deal terms or timing.
- Negative Sentiment: A shareholder law firm (Kahn Swick & Foti) opened an investigation into the adequacy of the $53 per‑share price and the sale process, which could lead to litigation or delay and adds execution risk. Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. – TERN
- Negative Sentiment: Several brokers trimmed coverage or lowered stances to “Hold” (Citizens/JMP, TD Cowen), reducing near‑term buy-side reinforcement; TD Cowen’s $53 target effectively prices the deal in with little upside. Benzinga
Analysts Set New Price Targets
TERN has been the topic of a number of recent research reports. Barclays increased their price target on Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Wall Street Zen downgraded Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. BMO Capital Markets increased their target price on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Oppenheimer upped their price target on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Finally, Mizuho upped their target price on Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $56.90.
Terns Pharmaceuticals Stock Down 0.5%
The firm has a market capitalization of $5.49 billion, a PE ratio of -51.38 and a beta of -0.31. The company’s 50-day simple moving average is $41.28 and its 200 day simple moving average is $29.06.
Insider Buying and Selling
In other news, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the sale, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Amy L. Burroughs sold 14,583 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $46.71, for a total value of $681,171.93. Following the completion of the sale, the chief executive officer directly owned 288,976 shares of the company’s stock, valued at $13,498,068.96. The trade was a 4.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 170,409 shares of company stock valued at $6,563,769 in the last three months. 1.50% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Terns Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in TERN. Avoro Capital Advisors LLC purchased a new stake in shares of Terns Pharmaceuticals during the fourth quarter worth about $175,740,000. Seven Fleet Capital Management LP purchased a new position in shares of Terns Pharmaceuticals in the 4th quarter valued at approximately $1,491,000. Invesco Ltd. boosted its stake in Terns Pharmaceuticals by 26.9% in the 4th quarter. Invesco Ltd. now owns 606,247 shares of the company’s stock worth $24,492,000 after purchasing an additional 128,573 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in Terns Pharmaceuticals in the 4th quarter worth approximately $215,000. Finally, NewEdge Advisors LLC grew its position in Terns Pharmaceuticals by 240.0% during the 4th quarter. NewEdge Advisors LLC now owns 9,173 shares of the company’s stock worth $371,000 after purchasing an additional 6,475 shares during the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.
Terns Pharmaceuticals Company Profile
Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.
The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.
See Also
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
